Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Average PT from Brokerages

Shares of Precigen, Inc. (NASDAQ:PGEN) have received a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.00.

A number of equities research analysts have recently commented on PGEN shares. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd.

Precigen Stock Up 3.4 %

NASDAQ:PGEN opened at $1.80 on Tuesday. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17. The stock has a market capitalization of $527.16 million, a PE ratio of -3.27 and a beta of 1.57. The stock’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.13.

Institutional Trading of Precigen

Several institutional investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. increased its holdings in Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 5,915 shares during the last quarter. Invesco Ltd. increased its holdings in Precigen by 14.6% in the 4th quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 6,040 shares during the last quarter. ProShare Advisors LLC increased its holdings in Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 10,900 shares during the last quarter. Stoneridge Investment Partners LLC grew its stake in shares of Precigen by 21.3% in the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 12,063 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Precigen by 12.0% in the fourth quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 12,285 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.